%0 Journal Article
%A Kekre, Natasha
%A Marquez-Malaver, Francisco J
%A Cabrero, Monica
%A Piñana, Jl
%A Esquirol, Albert
%A Soiffer, Robert J
%A Caballero, Dolores
%A Terol, M J
%A Martino, Rodrigo
%A Antin, Joseph H
%A Lopez-Corral, L
%A Solano, Carlos
%A Armand, Philippe
%A Pérez-Simon, Jose A
%T Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma.
%D 2016
%U http://hdl.handle.net/10668/10311
%X There is at present little data to guide the choice of conditioning for patients with lymphoma undergoing reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (SCT). In this study, we compared the outcomes of patients undergoing RIC SCT who received fludarabine and melphalan (FluMel), the standard RIC regimen used by the Spanish Group of Transplantation, and fludarabine and busulfan (FluBu), the standard RIC regimen used by the Dana-Farber Cancer Institute/Brigham and Women's Hospital. We analyzed 136 patients undergoing RIC SCT for lymphoma with either FluBu (n = 61) or FluMel (n = 75) conditioning between 2007 and 2014. Median follow-up was 36 months. The cumulative incidence of grades II to IV acute graft-versus-host disease (GVHD) was 13% with FluBu and 36% with FluMel (P = .002). The cumulative incidence of nonrelapse mortality (NRM) at 1 year was 3.3% with FluBu and 31% with FluMel (P 
%K Allogeneic
%K Busulfan
%K Fludarabine
%K Lymphoma
%K Melphalan
%K Reduced-intensity conditioning
%K Stem cell transplantation
%~